Clinical Trials · NCT01857895
Feasibility Study of Exenatide by Continuous Subcutaneous Infusion
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 10
- Start date
- May 2013
- Locations
- 1 site, United States
- Primary endpoint
- Characterization of interruptions or deviations from prescribed exenatide infusion in Part A